LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) announced that the results of the first double-blind, placebo-controlled study utilizing Hythiam’s PROMETA® Treatment Program (PROMETA) were presented yesterday at the College on Problems of Drug Dependence (CPDD) conference in San Juan, Puerto Rico, by addiction expert Harold C. Urschel, III, M.D., M.M.A. The 30-day study focused on evaluating the impact of PROMETA on cravings during the treatment of methamphetamine dependence, and was designed as a follow-up to Dr. Urschel’s 90-day open-label study on the effects of PROMETA in treatment-seeking, methamphetamine-dependent individuals.
